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Abstract
Background: The incidence of melanoma is considerably increasing worldwide. Frequent failing of classical
treatments led to development of novel therapeutic strategies aiming at managing advanced forms of this skin
cancer. Additionally, the implication of the endocannabinoid system in malignancy is actively investigated.
Methods: We investigated the cytotoxicity of endocannabinoids and their hydrolysis inhibitors on the murine B16
melanoma cell line using a MTT test. Enzyme and receptor expression was measured by RT-PCR and enzymatic
degradation of endocannabinoids using radiolabeled substrates. Cell death was assessed by Annexin-V/Propidium
iodine staining. Tumors were induced in C57BL/6 mice by s.c. flank injection of B16 melanoma cells. Mice were
injected i.p. for six days with vehicle or treatment, and tumor size was measured each day and weighted at the
end of the treatment. Haematoxylin-Eosin staining and TUNEL assay were performed to quantify necrosis and
apoptosis in the tumor and endocannabinoid levels were quantified by HPLC-MS. Tube formation assay and CD31
immunostaining were used to evaluate the antiangiogenic effects of the treatments.
Results: The N-arachidonoylethanolamine (anandamide, AEA), 2-arachidonoylglycerol and N-
palmitoylethanolamine (PEA) reduced viability of B16 cells. The association of PEA with the fatty acid amide
hydrolase (FAAH) inhibitor URB597 considerably reduced cell viability consequently to an inhibition of PEA
hydrolysis and an increase of PEA levels. The increase of cell death observed with this combination of molecules
was confirmed in vivo where only co-treatment with both PEA and URB597 led to decreased melanoma
progression. The antiproliferative action of the treatment was associated with an elevation of PEA levels and larger
necrotic regions in the tumor.
Conclusions: This study suggests the interest of targeting the endocannabinoid system in the management of
skin cancer and underlines the advantage of associating endocannabinoids with enzymatic hydrolysis inhibitors.
This may contribute to the improvement of long-term palliation or cure of melanoma.
Background
Melanoma is a malignant tumor of melanocytes with a
rate of incidence considerably increasing worldwide and
a poor prognosis [1]. Prevention and early detection are
the most successful measures against this skin cancer.
Management of advanced and metastatic melanoma cur-
rently consists of cytokine therapy and chemotherapy
with drugs including Dacarbazine which is the most
active single agent [2,3]. Nevertheless, frequent failing of
conventional treatments led to development of novel
therapeutic strategies for improvement of long-term pal-
liation or cure of melanoma.
The implication of the endocannabinoid system in cell
proliferation, differentiation and survival is now well
recognized. Besides endocannabinoid levels and receptor
expression varying frequently in cancer process, canna-
binoids modify cell fate and decrease tumor proliferation
and propagation [4]. The endocannabinoid system is
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tors CB1 and CB2, endogenous ligands binding to the
cannabinoid receptors (i.e. endocannabinoids) [5,6], as
well as proteins implicated in their synthesis and degra-
dation. N-arachidonoylethanolamine (AEA, anandamide)
and 2-arachidonoylglycerol (2-AG) are the two major
bioactive lipids activating the cannabinoids receptors [7].
Additionally, other endogenous mediators associated to
the endocannabinoid system, including N-palmitoyletha-
nolamine (PEA), exert their effects without binding to
the CB1 and CB2 cannabinoid receptors. Indeed, many
studies indicate that cannabinoids can also regulate cell
functions independently of CB1 and CB2 cannabinoid
receptors. Apart from binding to cannabinoid receptors,
endocannabinoids can activate the vanilloid receptor 1
(TRPV1) [8], two G protein-coupled receptors - GPR55
and GPR119 [9] - as well as the peroxisome prolifera-
tor-activated receptors (PPAR’s) [10]. The inactivation
of endocannabinoids belonging to the N-acylethanola-
mine family - AEA and PEA - occurs essentially by
enzymatic hydrolysis by the fatty acid amide hydrolase
(FAAH) [11]. The N-acylethanolamine-hydrolyzing acid
amidase (NAAA) also hydrolyses these endocannabi-
noids according to the same reaction with PEA as the
preferred substrate [12]. On the other hand, 2-AG levels
are for the most part regulated by the monoacylglycerol
lipase (MAGL) [13,14] even though the alpha/beta-
hydrolases 6 and 12 (ABHD6 and ABHD12) were also
described to hydrolyse 2-AG [15,16].
Endocannabinoids were reported to induce growth
arrest [17-20], to induce apoptosis and necrosis [21-23],
to inhibit angiogenesis [24] and to possess antimetastatic
effects [25-28]. Conversely, PEA was described to be
devoid of antiproliferative properties by itself although it
can act as an “entourage” agent by enhancing AEA cyto-
static effects. This might be attributed to a down-regula-
tion of FAAH expression or to a modulation of TRPV1
activity resulting in increased AEA mediated effects
[29,30]. Blazquez et al. revealed the potential benefits of
the cannabinoid system in the treatment of cutaneous
melanoma. They showed that cannabinoid receptor ago-
nists could decrease growth, proliferation, angiogenesis
and metastasis of this malignant cancer [31].
In the present study, we further demonstrate the
implication of endocannabinoids in malignancy and sug-
gest the interesting possibility of developing antimela-
noma therapies targeting the endocannabinoid system.
Thus, we investigated whether increasing endocannabi-
noid levels, either by direct administration or by redu-
cing their enzymatic degradation, or both, has an impact
on the growth of an aggressive skin cancer cell line. By
enhancing PEA levels through the inhibition of its
FAAH-mediated hydrolysis and by direct administration,
we put into light the possibility of potentiating the
increase of B16 melanoma cell death and slowing tumor
progression.
Methods
Drugs
N-palmitoylethanolamine and palmitic acid were
obtained from Tocris Bioscience. The enzyme inhibitors
URB597, CAY10402 and CAY10499 were bought from
Cayman Europe and MAFP from Tocris Bioscience.
CCP (N-cyclohexanecarbonylpentadecylamine) was
kindly synthesized in our lab by Coco N. Kapanda (Uni-
versité catholique de Louvain, Belgium) according to the
synthetic procedure described by Vandevoorde [32] and
Tsuboi [33]. All the receptor antagonists (AM251, cap-
sazepine, GW6471, T0070907 and (-)-cannabidiol) were
purchased from Tocris Bioscience. All drugs were pre-
pared as 20 mM stock solutions in DMSO and extem-
poraneously diluted in media for the experiments
conducted on cells. The final concentration of DMSO
was kept below 0.2%. [
3H]-anandamide (60 Ci/mmol),
[
3H]-2-oleoylglycerol (40 Ci/mmol) and [
3H]-PEA (20
Ci/mmol) were purchased from American Radiolabeled
Chemicals (St Louis, MO, USA).
Cell culture and mouse model
The murine melanoma cell line B16 was obtained from
t h eA m e r i c a nT y p eC u l t u r eC ollection and routinely
cultured in Minimum Essential Medium (MEM) a med-
ium supplemented with 10% fetal bovine serum, 100 UI/
ml penicillin, 100 mg/ml streptomycin and MEM Vita-
mins Solution. The human melanoma cell line MZ2-
MEL.43 was kindly given by Pierre Coulie (Université
catholique de Louvain, Belgium) and cultured in Iscove’s
medium supplemented with 10% fetal calf serum. Cells
were maintained at 37°C in a humidified atmosphere of
5% CO2.
Tumors were induced in 5 week-old male C57BL/6
mice (Elevage Janvier, France) by s.c. flank injection of
10
6 B16 melanoma cells. When the tumor reached a
volume of 20-40 mm
3, mice were randomly divided in
groups and injected i.p. for six days with vehicle or
treatment (either PEA and/or URB597 at 10 mg/kg/day,
daily). Tumor size was calculated according to the fol-
lowing formula: (4π/3) × (width/2)
2 × (length/2). The
procedure was approved by a local ethical review com-
mittee according to national animal care regulations.
Enzymatic activity and inhibition
On cell homogenates
In order to detect a hydrolytic activity for N-acylethano-
lamines (AEA and PEA) or 2-monoacylglycerols (2-
oleoylglycerol, 2-OG) in B16 cells, radiolabeled sub-
strates - either [
3H]-anandamide, [
3H]-2-oleoylglycerol
or [
3H]-N-palmitoylethanolamine (25 μl, 50000 dpm, 1
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with increasing amounts of cell homogenates (160 μl, 10
mM Tris-HCl, 1 mM EDTA, pH 7.4) and 10 μlo f
DMSO. Reactions were stopped by rapidly placing the
tubes in ice-cold water, followed by the addition of cold
chloroform-methanol (1:1 v/v, 400 μl). After centrifuga-
tion (850 g, 5 min, 4°C), the radioactivity in the aqueous
phase (200 μl) was counted by liquid scintillation (Ulti-
maGold from Perkin-Elmer). To estimate the inhibition
potential on B16 cell homogenates of the inhibitors, a
set amount of homogenate was chosen (25 μgo fp r o -
tein/tube) and compounds in DMSO (10 μl), or DMSO
alone for control, were added. As control for chemical
hydrolysis, dpm values obtained for tubes containing
buffer instead of proteins were systematically subtracted.
On living cells
Cells were seeded 24 h before treatment at a concentra-
tion of 10
5 cells/well in a 24-well plate. The medium
was removed and replaced by 200 μl of fresh medium
30 min before the beginning of the experiment. Test
compounds were added to each well (150 μl) followed
by the radiolabeled substrate (50 μl, 50000 dpm, 1 μM)
and the plate was incubated 10 min at 37°C in a 5%
CO2 humidified atmosphere. The reaction was stopped
by adding 400 μl of cold methanol on ice. After scraping
the wells, a volume of 600 μl was removed and placed in
ag l a s st u b ew h e r e3 0 0μl chloroform were added. The
tubes were centrifuged (850 g, 10 min, 4°C) and a 400 μl
aliquot of the aqueous upper phase was used to measure
the radioactivity by liquid scintillation (UltimaGold from
Perkin-Elmer). Cells incubated with vehicle (DMSO)
were used as control and wells containing no cells were
used as blank.
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from the cultured cells with
the TriPure Isolation reagent (Roche). To measure
mRNA expression, reverse transcription was performed
using the Reverse Transcription System (Promega) and
the generated cDNA was amplified by PCR using the
primers mentioned in the Table 1. Polymerase chain
reactions were performed according to the following
parameters: 95°C for 10 min, 95°C for 3 s, 60°C for 26 s,
and 72°C for 10s (45 cycles). After amplification, agarose
gel electrophoresis was used to detect the expression of
the genes.
Quantitative PCR (qPCR) was performed to study the
quantitative mRNA expression of the FAAH and the
NAAA. RPL19 was used as house keeping gene. The
samples were run in a 96-well reaction plate and data
were analyzed according to the 2
-ΔCT method.
MTT cell viability assay
The effect on cell viability of the different treatments
was measured using MTT assay, which is based on the
transformation of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) in formazan crystals by
the mitochondrial succinate dehydrogenase of viable
cells. Cells were plated in 96-well plates at a density of
2000 cells/well in medium supplemented with 10%
serum. After 5 h of incubation at 37°C in a 5% CO2
humidified atmosphere, test compounds diluted in cul-
ture medium were added in each well for 24 h, 48 h or
72 h. The medium was then removed and 100 μlo f
MTT solution (0.3 mg/ml) were added for a 2 h incuba-
tion. The MTT solution was removed, replaced by 100
μl DMSO to dissolve the crystalline formazan product
and the absorbance was read at 570 nm (with a reading
at 650 nm as reference) using a microplate
spectrophotometer.
For the treatments with the receptor antagonists, only
the 72 h time point was considered and the antagonists
were added 1 h before the beginning of the cytotoxic
treatment.
Annexin-V/propidium iodide staining
Detection and quantification of apoptosis was performed
by the analysis of phosphatidylserine on the outer leaflet
of apoptotic cell membranes using Annexin-V-Fluores-
cein. Propidium iodide was used for the differentiation
Table 1 Primer sequences used for PCR amplification
RPL19 F: gaaggtcaaagggaatgtgttca FAAH F: gagatgtatcgccagtccgt
R: ccttgtctgccttcagcttgt R: acaggcaggcctataccctt
MAGL F: atggtcctgatttcacctctggt NAAA F: ggttttatccctgtttcctgtttat
R: tcaacctccgacttgttccgagaca R: tttttgacaatacatcaccttcagct
CB1 F: ctgatgttctggatcggagtc CB2 F: tgacaaatgacacccagtcttct
R: tctgaggtgtgaatgatgatgc R: actgctcaggatcatgtactcctt
GPR55 F: atttggagcagaggcacgaacatga TRPV1 F: aactcttacaacagcctgtattccaca
R: agtggcgatatagtccagcttcct R: aagacagccttgaagtcatagttct
PPARa F: caacggcgtcgaagacaaa PPARg F: ctgctcaagtatggtgtccatga
R: tgacggtctccacggacat R: tgagatgaggactccatctttattca
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the cytotoxic treatment before being stained with the
Roche Annexin-V-FLUOS Staining kit (Mannheim, Ger-
many) following the manufacturer’si n s t r u c t i o n s .C e l l s
were examined using a fluorescence microscope from
Optika (Ponteranica, Italy). Pictures were taken with a
Moticam 2300 from Motic (Hong Kong, China).
Endocannabinoid quantification by HPLC-MS
Cells (10
7 cells/condition) were seeded in 10% FBS
media for 12 h prior to the incubation (8 h) with drugs,
or vehicle, in 1% FBS media. Cells and media were then
recovered and the lipids extracted, in the presence of
deuterated standards (200 pmol), by adding 14 ml of
chloroform and 7 ml of methanol. Following vigorous
mixing and sonication, the samples were centrifuged
and the organic layer was recovered and then dried
under a stream of N2.
Endocannabinoid levels in B16 tumors were quantified
by directly homogenizing the tissue in chloroform (14
ml) before adding the deuterated standards, methanol (7
ml) and water (3.5 ml). After mixing and phase separa-
tion by centrifugation, the organic layer was recovered
and dried under a stream of N2.
Both for cells and tumors, the resulting lipid extracts
were purified by solid-phase extraction using silica and
elution with an EtOAc-Acetone (1:1) solution [34,35].
The resulting lipid fraction was analysed by HPLC-MS
using an LTQ Orbitrap mass spectrometer (Thermo-
Fisher Scientific) coupled to an Accela HPLC system
(ThermoFisher Scientific) [36]. Analyte separation was
achieved using a C-18 Supelguard pre-column and a
Supelcosil LC-18 column (3 μM, 4.6 × 150 mm) (Sigma-
Aldrich). Mobile phases A and B were composed of
MeOH-H2O-acetic acid 75:25:0.1 (v/v/v) and MeOH-
acetic acid 100:0.1 (v/v), respectively. The gradient (0.5
ml/min) was designed as follows: transition from 100%
A to 100% B linearly over 15 min, followed by 10 min
at 100% B and subsequent re-equilibration at 100% A.
We performed MS analysis in the positive mode with an
APCI ionisation source. The capillary and APCI vapori-
ser temperatures were set at 250°C and 400°C, respec-
tively. N-acylethanolamines were quantified by isotope
dilution using their respective deuterated standards with
identical retention [34]. The data were normalized by
cell number in the in vitro experiments and by tumor
sample weight in the in vivo testing.
Histology
Tumors were excised after five or six days of treatment
with tested compounds or vehicle and either fixed in 4%
paraformaldehyde or embedded in O.C.T. compound for
standard paraffin sections or for cryosectioning, respec-
tively. Tissue samples were sliced in 5 μm sections for
paraffin samples and 10 μm sections for frozen samples.
The paraffin sections were stained with Haematoxylin &
Eosin and photographed on a Zeiss MIRAX microscope
to allow a global overview of tumor necrosis. Induction
of apoptosis was assessed by TUNEL assay using an in
situ cell death detection kit (Roche Diagnostics, Vil-
voorde, Belgium) on frozen slices. Vascularization was
evaluated by immunostaining of tumor cryosections
using an antibody directed against CD31 (BD Bios-
ciences, San Jose, CA). Nuclei were also counterstained
with 4,6-diamidino-2-phenylindole (DAPI). Necrosis,
apoptosis and blood vessel area were quantified using
Frida software and expressed as a percentage of the
whole tumor area.
Tube formation assay
The antiangiogenic effect of the different treatments was
determined by seeding 15 × 10
3 endothelial cells
(HUVEC) in 96-well plates containing Matrigel (BD
Biosciences). Formation of capillary-like tubular struc-
tures was quantified by counting the number of tube
intersections in each well.
Statistical analysis
Values were expressed as mean ± SEM. Statistical analy-
sis was performed by ANOVA or by unpaired Student’s
t test.
Results
Hydrolysis and cytotoxicity of AEA, 2-AG and PEA in B16
cells
In order to evaluate the hydrolysis of AEA, 2-AG and
PEA, we used [
3H]-AEA, [
3H]-2-OG and [
3H]-PEA and
found that B16 cell homogenates significantly hydro-
lyzed endocannabinoids (Figure 1A). When looking for
the expression of enzymes responsible for endocannabi-
noid hydrolysis, we detected mRNA expression of the
major endocannabinoid degrading enzymes, i.e. FAAH,
NAAA and MAGL (Figure 1B). Since the aim of this
work was to increase endocannabinoid cytotoxicity by
inhibiting their hydrolysis, we ensured that AEA, 2-AG
and PEA reduced cell viability in our B16 model using a
MTT test. We observed that at 10 μM and already after
24 h of treatment, AEA, 2-AG and PEA decreased cell
viability, in comparison to vehicle (Figure 1C). This
effect was amplified after 48 h and 72 h of incubation
and was slightly more pronounced for PEA. Therefore,
we further investigated the cytotoxic effect of PEA and
obtained a dose-response when this molecule was tested
at 1, 10 and 20 μM for 72 h (Figure 1D). Because endo-
cannabinoids’ fatty acid metabolites are known to pos-
sess numerous functions we tested whether they affect
cell viability of B16 cells. We found that neither palmitic
acid (Figure 1E) nor arachidonic acid (data not shown)
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our hypothesis that increasing endocannabinoid levels,
by blocking their degradation, would reduce tumor cell
viability.
Inhibition of N-palmitoylethanolamine degradation
Five inhibitors that were reported to decrease N-palmi-
toylethanolamine hydrolysis either by inhibiting FAAH
(URB597, CAY10402, MAFP and CAY10499) or NAAA
(CCP) (see Additional file 1) were tested at 1 μMa n d
10 μM on total cell homogenates. The inhibition assays
were also performed on intact cells in culture to confirm
that the inhibitors do reach their targets in culture con-
ditions (Table 2).
We observed that URB597, CAY10402, MAFP and
CAY10499 all inhibit PEA hydrolysis in homogenates
and cultured cells even though the inhibition is slightly
less pronounced in the latter case. Note that the use of
CCP did not reduce PEA hydrolysis in homogenates and
only decrease it by 26% ± 7.0 in intact cells at 10 μM.
The absence of inhibition observed in homogenates
compared to cells in culture could be explained by a
NAAA activity known to be the highest at acidic pH
while the assay was performed on homogenates at
Figure 1 Enzymatic hydrolysis and cytotoxicity of AEA, 2-AG and PEA in B16 melanoma cells.( A) Enzymatic activities for AEA, 2-AG and
PEA hydrolysis were measured in B16 cell homogenates using [
3H]-AEA, [
3H]-2-OG and [
3H]-PEA, respectively. Data are the mean of three
experiments performed in duplicate. (B) B16 cells express endocannabinoid degrading enzymes FAAH, NAAA and MAGL. Detection of mRNA
was performed by RT-PCR using respectively mouse liver, lung and brain as control and RPL19 as house keeping gene (blot representative of
three). (C) The endocannabinoids AEA, 2-AG and PEA decrease B16 cell viability. Cells were seeded 5 h before treatment (2000 cells/well in
microwells) and incubated with 10 μM of endocannabinoids. After 24 h, 48 h or 72 h of treatment, cytotoxicity was assessed by a MTT test. Data
are expressed as percentage of the vehicle control and are the mean of three experiments performed in quintuplicate. Significantly different (**P
< 0.01) from vehicle incubation. (D) PEA dose-dependently decreases B16 cell viability. The cells were incubated with 1 μM, 10 μM and 20 μMo f
PEA. After 72 h of treatment, cytotoxicity was assessed by a MTT test. Data are expressed as percentage of the vehicle control and are the mean
of three experiments performed in quintuplicate. Significantly different (**P < 0,01) from vehicle incubation. (E) Palmitic acid does not decrease
B16 viability. The cells were incubated with 1 μM, 10 μM and 20 μM of palmitic acid. After 72 h of treatment, cytotoxicity was assessed by a MTT
test. Data are expressed as percentage of the vehicle control and are the mean of three experiments performed in quintuplicate.
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FAAH and NAAA mRNA expression were also per-
formed in order to investigate the possibility that a high
level of FAAH, in comparison to NAAA, could lead to
the lack of efficacy of CCP on PEA hydrolysis in our
system. The results indicated that the relative mRNA
levels of the two enzymes were in the same order of
magnitude (Figure 2) and thus the lack of NAAA
expression at the mRNA levels does not account for the
inefficiency of CCP.
Increase of N-palmitoylethanolamine effects on B16 cell
viability by hydrolysis inhibitors
Next, PEA (10 μM) was co-incubated for 72 h with the
FAAH inhibitors - URB597, CAY10402, MAFP,
CAY10499 - and the NAAA inhibitor - CCP - at 10
μM, with the objective of enhancing individual effect on
cell viability (Figure 3A). All four inhibitors enhanced
PEA-induced cytotoxicity although the effect was more
pronounced with the selective inhibitors (URB597,
CAY10402) as compared to the dual FAAH/MAGL
inhibitors (MAFP, CAY10499). Of note, the co-incuba-
tion of PEA and URB597 dramatically reduced cell via-
bility which was no more than 11% of the vehicle
control after 72 h of treatment. In line with the results
obtained in the enzymatic inhibition assay, CCP had no
potentiating effect on cytotoxicity when added to PEA.
The effects on cell viability of the inhibitors alone
were also evaluated at 10 μM and after 72 h of incuba-
tion. We did not use CCP anymore because it was poor
at inhibiting PEA hydrolysis in our cellular model and
did not induce supplemental cytotoxicity when co-incu-
bated with PEA. Only the three FAAH inhibitors
URB597, MAFP and CAY10499 provoked a significant
increase in cytotoxicity while the reversible FAAH
inhibitor CAY10402 did not influence cell viability (Fig-
ure 3B).
Because the PEA-URB597 combination produced the
highest cytotoxicity (Figure 3A), we focused on these
compounds for the next experiments. We wondered if
URB597 could exert its cytotoxicity through inhibition
of FAAH and subsequent increase of PEA concentra-
tions in our conditions. For this purpose, PEA levels
were measured in B16 cells using an isotope-dilution
HPLC-MS method and we observed that incubating B16
cells with URB597 (1 μM, 8 h) resulted in increased
PEA levels (163 ± 13% of the control) (Figure 3C).
PEA and URB597 potentiate cell death of B16 melanoma
cells
We next looked at the influence of PEA and URB597 on
cell death by measuring annexin-V positive cells (A+/PI-
) and double stained cells (A+/PI+) representing apopto-
tic and necrotic (or late apoptotic) cells, respectively.
Translocation of phosphatidylserine is an early event in
apoptosis and its measurement allows the detection of
cells undergoing caspase-dependent or independent
apoptosis. Treatment of B16 cells with PEA or URB597
Table 2 Inhibition of PEA hydrolysis in B16
PEA hydrolysis inhibition (% ± SEM)
Cell homogenates Intact cells
URB597 10 μM 95 ± 1.0 93 ± 3.7
1 μM 90 ± 4.1 85 ± 5.2
CAY10402 10 μM 95 ± 6.3 75 ± 4.6
1 μM 83 ± 5.2 65 ± 5.1
MAFP 10 μM 86 ± 6.3 70 ± 4.2
1 μM 88 ± 3.1 75 ± 3.0
CAY10499 10 μM 100 ± 7.5 80 ± 4.4
1 μM 91 ± 3.9 64 ± 4.9
CCP 10 μM 6 ± 4.2 26 ± 6.8
1 μM 4 ± 5.6 26 ± 7.0
FAAH inhibitors (URB597, CAY10402), dual FAAH/MAGL inhibitors (MAFP,
CAY10499) and NAAA inhibitor (CCP) were tested at concentrations of 1 and
10 μM on cell homogenates (25 μg protein, pH 7.4) and on living cells (10
5
cells/well, seeded 24 h before) in culture medium. Data are the mean of three
experiments and are expressed as percentage of the control containing
vehicle instead of the inhibitors
Figure 2 FAAH and NAAA mRNA relative expression in B16
cells. Quantitative detection of mRNA was performed by qPCR
using RPL19 as house keeping gene. Data were analyzed according
to the 2
-ΔCT method and the NAAA mRNA expression is set at 1
value.
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dead cells as compared to vehicle, even though PEA
tended to enhance cell death (Figure 4). On the con-
trary, co-incubation with PEA and URB597 increased
the percentage of cells dying by both apoptosis and
necrosis.
We then asked if the cytotoxic effects of the PEA-
URB597 combination could be mediated by the classical
molecular targets of endocannabinoids. Thus, we co-
incubated PEA, URB597 or PEA-URB597 with AM251
(0.1 and 1 μM), capsazepine (0.1 and 1 μM), GW6471
(1 and 5 μM), T0070107 (1 and 5 μM) and cannabidiol
(1 and 10 μM). These compounds are selective antago-
nists of the CB1, TRPV1, PPARa, PPARg and GPR55
receptors respectively, the mRNA of which were found
in B16 melanoma cells (see Additional file 2). None of
the antagonists reduced the effect of PEA (10 μM) or
URB597 (10 μM) alone or in combination (see Addi-
tional file 3). We would like to point out that antagonist
concentrations were selected according to the literature
and that we tested their own cytotoxicity to exclude the
possibility that they could affect B16 cell viability by
themselves (see Additional file 4). At 10 μM, cannabidiol
has enhanced the cytotoxic effect of PEA and URB597
when each of these drugs was used alone. One
Figure 4 PEA and URB597 potentiate cell death of B16
melanoma cells. Apoptosis was assessed by Annexin-V (A)/
Propidium Iodide (PI) staining. B16 cells were treated with 10 μMo f
PEA and/or URB597 for 24 h and the number of Annexin-V positive
cells (A+/PI-, apoptotic) and of double stained cells (A+/PI+,
necrotic) was expressed as a percentage of total cells. Data are the
average of five random fields from experiments performed in
triplicate. Significantly different (**P < 0.01) from vehicle incubation.
Figure 3 Enhancement of PEA effects on B16 cell viability by
hydrolysis inhibitors. (A) The FAAH inhibitors (URB597, CAY10402)
and dual FAAH/MAGL inhibitors (MAFP, CAY10499) potentiate PEA
cytotoxicity. B16 cells were seeded 5 h before treatment (2000 cells/
well in microwells) and incubated with PEA (10 μM) with or without
URB597, CAY10402, MAFP, CAY10499 or CCP (at 10 μM). After 72 h
of treatment, cytotoxicity was assessed by a MTT test. Data are the
mean of three experiments (performed in quintuplicate) and are
expressed as percentage of the vehicle control. Significantly
different (**P < 0.01) from PEA incubation. (B) URB597, MAFP and
CAY10499 slightly decrease B16 cell viability. Cells were seeded 5 h
before treatment (2000 cells/well in microwells) and incubated with
inhibitors at a concentration of 10 μM. After 72 h of treatment,
cytotoxicity was assessed by a MTT test. Data are the mean of three
experiments performed in quintuplicate and are expressed as
percentage of the vehicle control. Significantly different (**P < 0.01)
from vehicle incubation. (C) URB597 increases intracellular levels of
PEA as measured by HPLC-MS. B16 cells were incubated for 8 h
with URB597 (1 μM). We found in control cells 25.4 ± 3.8 pmol of
PEA/10
7 cells. Data are the mean of three experiments performed in
quadruplicate and are expressed as percentage of the vehicle
control. Significantly different (***P < 0.001) from vehicle incubation.
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Page 7 of 14explanation is that this compound is a weak agonist of
the TRPV1 and was shown to activate this receptor in
this range of concentrations [37].
In vivo co-administration of PEA and URB597 reduces
melanoma growth
Since PEA and URB597 were able to induce cell death
when used in co-incubation in vitro, we wanted to con-
firm that this was also the case in vivo. Therefore, we
evaluated their effect on malignant melanoma growth in
C57BL/6 mice. Tumors were generated by subcutaneous
injection of B16 cells, and when tumors reached a
volume of approximately 20-40 mm
3,m i c ew e r et r e a t e d
by intraperitoneal injections of vehicle, PEA and/or
URB597 for up to six days. The tumor size of mice trea-
ted with PEA or URB597 alone were not significantly
different from those injected with vehicle. However, co-
administration of PEA and URB597 resulted in a signifi-
cantly reduction of tumor growth and of their size at
the end of the experiment (Figure 5A). We also
weighted tumors at the end of the experiment and
observed a significant difference between normal and
PEA/URB597 treated tumors (Figure 5B).
With the aim to correlate the anticancerous effect of
PEA and URB597 with endocannabinoid levels inside
the tumor, we measured AEA, 2-AG and PEA amounts
in the excised tumors by HPLC-MS. On the one hand,
AEA and 2-AG levels were not significantly affected by
PEA, URB597 or both molecules injection, even though
AEA concentration tended to increase after URB597 or
PEA/URB597 treatments (Figure 6A, B). On the other
hand, PEA levels were increased after co-treatment with
P E Aa n dU R B 5 9 7b u tn o ti ft h e s ec o m p o u n d sw e r e
injected alone, even though a trend towards increased
levels was observed following URB597 administration
(Figure 6C).
PEA and URB597 co-administration induces tumor
necrosis
Necrosis and apoptosis were quantified on tumor slices
after Haematoxylin & Eosin (H&E) and TUNEL staining
respectively. Tumors were excised after six days of co-
treatment with PEA and URB597. Vehicle-treated
tumors were excised after five or six days of injection in
order to be able to compare either tumor treated during
the same period of time, or tumors having the same
volume at the end of the experiment. Indeed, we
observed that size of six days drug-treated tumors and
five days vehicle-treated tumors did not significantly dif-
fer (Figure 5A, B). It is known that more voluminous
tumors may present larger necrotic regions and we
wanted to exclude this artifact. Here we show that
tumors co-treated with PEA and URB597 present
enlarged necrotic regions (53 ± 6%) as compared with
both tumors treated during five or six days with vehicle
(28 ± 3% and 38 ± 2% respectively) (Figure 7A). These
results were consistent with observations we made dur-
ing in vitro assays and demonstrate that drug treatment
delays tumor progression by provoking cell death. Figure
7B displays representative tumor slices after H&E stain-
ing. TUNEL assay on tumors slices did not show more
positively stained cells in treated tumors than in control
tumors (Figure 7C).
Finally, we wondered if the increase in the initial level
of necrosis produced by co-injection of PEA and
URB597 could be the result of vascular events. Thus we
performed an endothelial tube formation assay using
HUVEC. Here, PEA (10 μM) and URB597 (10 μM),
incubated alone or in co-incubation, did not alter the
capacity of endothelial cells to form tubes when cultured
on Matrigel (Figure 7D). Additionally, evaluation of
tumor vascularization by immunostaining did not reveal
any significant change in blood vessel area between trea-
ted and untreated mice (Figure 7E).
Figure 5 Co-administration of PEA and URB597 reduces
melanoma growth. Tumors were induced by s.c. injection of B16
cells in C57BL/6 mice. When tumor size reached a volume of
approximately 20-40 mm
2, animals were treated i.p. either with
vehicle (n = 18) or with PEA (= 7), URB597 (n = 7) or both
molecules (n = 20) (at 10 mg/kg/day, daily) for six days. (A) Tumor
volume was measured each day. (B) Weight of tumors treated with
vehicle (6 or 5 days of treatment) or PEA + URB597 (6 days of
treatment) was measured at the end of the experiment. Significantly
different (*P < 0.05; **P < 0.01; ***P < 0.001) from vehicle
administration.
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Page 8 of 14PEA and URB597 impair human melanoma viability
In a view to strengthen the potential interest of using
PEA and URB597-based treatment for melanoma
growth management, we measured the effect of these
compounds on a human melanoma cell line. URB597
(10 μM) slightly decreased cell viability of MZ2-MEL.43
melanoma, which was 90% of the vehicle control after
72 h of treatment. The cytotoxicity produced by PEA
(10 μM) led to a reduction of cell viability to 66%, while
it was potentiated by URB597 to reach 48% of residual
viable cells (Figure 8).
Discussion
The literature widely reports on the regulatory actions
of the endocannabinoid system in health and disease,
including cancer. Endocannabinoids and synthetic can-
nabinoids are essentially described as protective factors
limiting cell proliferation, differentiation and survival as
well as tumor development. In this study, we aimed at
investigating the possibility of enhancing endocannabi-
noid cytotoxicity using inhibitors of their hydrolysis in a
melanoma model.
After looking for the presence of enzymatic activity for
AEA, 2-AG and PEA hydrolysis and elucidating which
enzymes were present in our melanoma model, we
showed a time-dependent effect of these three endocan-
nabinoids on B16 cell viability. As frequently described
for many cancer cell lines like colon cancer cells [17,21],
glioma cells [20] breast cancer cells [19,25,27] or pros-
tate cancer cells [28], AEA and 2-AG reduced B16 cell
viability. Surprisingly, at 10 μM, we found PEA to
decrease cell viability. Indeed, this endocannabinoid was
reported to act as an “entourage” agent able to increase
AEA antiproliferative effects but not to induce those
when incubated alone, even at concentrations up to 10
μM [29,30]. However, here PEA could clearly reduce
B16 cell viability at 10 μM but also at lower concentra-
tions. We also confirmed that PEA degradation into pal-
mitic acid was not responsible for the effects observed
with PEA [38].
We then sought to increase PEA levels to investigate if
this could affect B16 melanoma cell viability by poten-
tiating PEA cytotoxicity. Some reports indicate that the
use of inhibitors of endocannabinoid hydrolysis can be
of interest in the development of anticancer therapies.
For example, elevation of endocannabinoid concentra-
tions by inhibitors of their re-uptake and degradation
produced a decrease in thyroid transformed cells growth
[39]. In a colorectal cancer cell line, inhibitors of endo-
cannabinoid inactivation increased their levels and
reduced cell proliferation [40]. Other experiments per-
formed on prostate cancer cells also testified of the ben-
efits of inhibiting 2-AG hydrolysis to block cell growth
and invasion [28,41-43]. Therefore, we assayed five
Figure 6 Tumor endocannabinoid levels.( A)A E A ,( B)2 - A Ga n d
(C) PEA levels were measured by HPLC-MS in tumor samples of
mice treated i.p. with vehicle (n = 15), PEA (n = 7), URB597 (n = 7)
or both molecules co-incubation (n = 15) (at 10 mg/kg/day, daily)
for six days. Basal levels are 78.4 ± 11.7 pmol/g, 1.55 ± 0.11 nmol/g
and 546.1 ± 55 pmol/g of tissue for AEA, 2-AG and PEA,
respectively. Significantly different (**P < 0.01) from vehicle
administration.
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Page 9 of 14inhibitors of either FAAH or NAAA, the two main
enzymes known to hydrolyze PEA and that we found to
be expressed in B16 melanoma cells. The most cytotoxic
treatment was obtained by the co-incubation of 10 μM
of PEA with the irreversible FAAH inhibitor, URB597 at
10 μM. Using a human melanoma cell line, we also evi-
denced a significant cytotoxicity of this treatment. Inter-
estingly, among the inhibitors tested, the highest
inhibition of PEA hydrolysis was obtained with URB597.
This compound already exerted a significant decrease in
cell viability when used alone. Of note, the other selec-
tive FAAH inhibitor CAY10402 was also able to potenti-
ate PEA cytotoxicity without inducing any decrease in
cell viability by itself. This last observation suggested
that the PEA-URB597 cytotoxicity might be partly due
to elevation of endocannabinoid levels. Indeed we found
that incubation of B16 cells with URB597 could raise
PEA levels up to 163%, indicating that the cytotoxicity
of this inhibitor could be partly assigned to modulation
of PEA levels. Actually, even though the concentrations
obtained when inhibiting FAAH were lower than those
required to reduce cell viability by adding PEA exogen-
ously, we considered that locally available PEA levels
m i g h tb eh i g he n o u g ht op r o d u c ep h a r m a c o l o g i c a l
effects when inhibiting FAAH. The higher effects, when
looking at PEA hydrolysis or at cell viability, of URB597
compared to CAY10402 could be related to a reversible
FAAH inhibition by CAY10402, while URB597 was
characterized as an irreversible inhibitor. In the liver,
URB597 was previously shown to enhance AEA-induced
Figure 7 PEA and URB597 increase tumor necrosis. Tumors treated daily by co-administration of PEA and URB597 were excised after six days
of treatment and tumors treated by vehicle were excised after five or six days. (A) Quantification of necrotic regions was realized using
Haematoxylin and Eosin staining (n = 5). Significantly different (*P < 0.05; **P < 0.01) from vehicle administration. (B) Pictures show
representative histological H-E stainings performed on tumor slices. (C) Apoptosis was evaluated by TUNEL assay (n = 6-12). (D) PEA and URB597
do not affect angiogenesis. HUVEC were seeded (10
4 cells/well in microwells) and incubated with PEA (10 μM) and/or URB597 (10 μM). The
angiogenic potency was determined by measuring the number of tube intersections formed after 24 h plating on Matrigel (n = 2). (E) Tumor
vascularization was evaluated by CD31 immunostaining of tumor cryosections and blood vessel area was expressed as percentage of the total
area (n = 5).
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Page 10 of 14cell death via FAAH inhibition [44]. Surprisingly, the
two dual FAAH/MAGL inhibitors MAFP and
CAY10499 only slightly accentuated PEA effects on cells
viability even though they were effective at inhibiting
PEA hydrolysis and exhibited cytotoxic effects by them-
selves. Nevertheless, in comparison to URB597, the
effect of MAFP on intracellular PEA levels was less pro-
nounced and CAY10499 did not significantly affect PEA
concentration even though it tended to increase it (see
Additional file 5A). It is therefore supposed that the
action of these two dual inhibitors is not sufficient to
increase PEA levels and, consequently, its cytotoxicity
upon melanoma cells. In addition, as mentioned above
these compounds are also irreversible inhibitors of
MAGL and consequently can influence 2-AG levels as
well (see Additional file 5B). The inhibition of 2-AG
degradation was frequently evidenced to result in antitu-
mor effects, either by making profit of 2-AG antiproli-
ferative and anti-invasive properties [40,41,43] or by
limiting the production of arachidonic acid known to be
associated to aggressiveness of cancer cells [45,46]. Since
this endocannabinoid also exhibited cytotoxic properties
in B16 cells, we would have assumed that the concomi-
tant inhibition of the FAAH and the MAGL should
have produced an enlarged diminution of cell viability.
Astonishingly, we only observed that inhibition of 2-AG
hydrolysis produced a small decrease in cell viability and
poorly contributed to induction of cytotoxicity when
combining to PEA. This suggests a minor role of 2-AG
in cell viability in our model as compared to PEA.
Finally, although the poor inhibition of PEA hydrolysis
by the NAAA inhibitor is puzzling at a first glance, the
almost full inhibition of PEA hydrolysis by URB597 sug-
g e s t st h a tF A A Hi sl i k e l yt oa c c o u n tf o rm o s to fP E A
degradation in our cellular model. Thus, even if CCP
inhibits the NAAA-mediated PEA hydrolysis, FAAH can
largely compensate for the decreased NAAA activity
[47].
The receptor mediating the cytotoxic effects of PEA
and URB597 could not be identified as one of the classi-
cal molecular targets mediating endocannabinoid action.
However, though pharmacological blockade of receptors
constitutes a reliable and widely used method, silencing
of these receptors may constitute a matter of interesting
perspective to completely rule out their implication in
the cytotoxic effects produced by the treatments.
Co-treatment of PEA and URB597 induced cell death
in cultured B16 melanoma cells, while PEA and URB597
incubated alone only slightly increased the number of
apoptotic and necrotic cells. This drug activity reinforce-
ment was confirmed in vivo where tumor volume and
tumor weight were decreased after 6 days of treatment
only when melanoma-bearing mice were treated with
both PEA and URB597. When looking at the endocan-
nabinoid levels in the tumor after treatment, the growth
delay induced by PEA-URB597 treatment appears to be
related to an elevation of PEA levels within the tumor.
Conversely, AEA and 2-AG levels were not significantly
affected by treatments even though AEA levels tended
to increase following URB597 injections. These results
contrast with the observations made by Bifulco et al.
with rat thyroid transformed cells, in which tumor levels
of AEA, 2-AG and PEA were all three augmented after
an intratumor treatment with the FAAH inhibitor ara-
chidonoyl-serotonin [39]. This difference may arise from
variations in the experimental conditions, such as the
injection modalities, resulting in variable availabilities of
the inhibitor, or the timing at which tumors were
resected. Since our results show a tendency to increase
for N-acylethanolamine concentrations in URB597-trea-
ted mice and since only the co-incubation of PEA and
URB597 increased PEA levels, we may think that the
elevation of AEA and PEA levels are transitory and that
these molecules are rapidly degraded. Along this line,
we support the hypothesis that an earlier excision of the
tumors after the last injection could have revealed a
Figure 8 PEA and URB597 impair human melanoma viability.
URB597 potentiates the decrease of MZ2-MEL.43 melanoma cell
viability produced by PEA. Cells were seeded 5 h before treatment
(2000 cells/well in microwells) and incubated with PEA (10 μM) with
or without URB597 (10 μM). After 72 h of treatment, cytotoxicity
was assessed by a MTT test. Data are expressed as percentage of
the vehicle control and are the mean of three experiments
performed in triplicate. Significantly different (**P < 0.01) from
vehicle incubation. Significantly different (###P < 0.001) from PEA
incubation.
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Nevertheless, in our melanoma system, only the co-
injection of PEA and URB597 is able to sufficiently
increase the concentrations in order to reduce tumor
growth. In addition, some reports have shown that
FAAH inhibition induces an increase in 2-AG levels
[39,41]. However, in our melanoma cells, 2-AG levels
were not influenced at all by URB597 treatments. This
may be attributed to the fact that FAAH is weakly
responsible for 2-AG hydrolysis in B16 cells.
We could also evidence that the decrease in tumor
growth observed with PEA-URB597 treatment was the
result of increased necrotic events in the tumor.
Although tumor growth delay obtained with PEA and
URB597 may look marginal, the extent of necrosis
observed in this very aggressive tumor model indicates
that measurements of tumor volume/weight certainly
underestimate the real impact of the co-treatment.
Furthermore, because neither PEA nor URB597 or the
association of both molecules produced antiangiogenic
effects, a reduced oxygen and nutrient supply is unlikely
to account for the increased necrosis induced by the
treatment. It seemed of interest to investigate this point
because PEA and analogues have already been described
as owning antiangiogenic effects in a model of chronic
inflammation [48,49]. Likewise, AEA was reported to
influence cancer growth via inhibition of angiogenesis
[24] and synthetic cannabinoids WIN-55.212-2 and
JWH-133 were shown to decrease melanoma vasculari-
zation [31].
A large number of reports suggest the therapeutic
interest of using PEA in medicine. This lipid mediator
has been emerging as a potent antinociceptive molecule
[50,51] and exhibits anti-inflammatory properties [52].
Of note, PEA is already used as the active molecule of
anti-inflammatory and analgesic preparations (e.g. Nor-
mast
®, Pelvilen
®) [53,54]. These advantageous effects
associated with the present observations put into light
the possibility of emerging therapies implicating PEA for
pathological conditions including cancer.
Conclusions
The current study demonstrates the potential implica-
tion of endocannabinoids in B16 melanoma cell survival.
Specifically, the supra-additive action of PEA and the
FAAH inhibitor URB597 promotes cell death and delays
in vivo tumor growth. Additionally, we confirmed that
antiangiogenic events are not responsible for the
enhanced necrosis observed in the tumors. Hence, this
report suggests the attractive prospect of designing
PEA-based anticancer therapies, with potential anti-
inflammatory and antinociceptive effects, via an inhibi-
tion of its hydrolysis.
Additional material
Additional file 1: Structures of the endocannabinoid metabolism
inhibitors used in this study.
Additional file 2: Receptor expression in B16 cells. B16 cells express
cannabinoid receptor CB1 but not CB2, G-protein coupled receptor
GPR55, vanilloid receptor TRPV1 and nuclear receptors PPARa and PPARg.
Detection of mRNA was performed by RT-PCR using mouse brain, spleen
and liver as control and RPL19 as house keeping gene. The blots are
representative of three.
Additional file 3: Investigation of the potential molecular targets of
PEA and URB597 in B16 cells. Cytotoxicity of PEA (10 μM), URB597 (10
μM) and PEA + URB597 was not significantly affected by CB1 receptor
antagonist (0.1 and 1 μM), TRPV1 receptor antagonist (0.1 and 1 μM),
PPAR’s receptor antagonists (1 and 5 μM) and GPR55 receptor antagonist
(1 and 10 μM). B16 cells were seeded 5 h before treatment (2000 cells/
well in microwells) and incubated with PEA alone (10 μM), URB597 alone
(10 μM) and combinations of these two molecules. Antagonists were
added 1 h prior to the addition of PEA and/or URB597. A MTT test was
used to evaluate the percentage of viable cells remaining after 72 h.
Data are the mean of three experiments performed in triplicate and are
expressed as percentage of the vehicle control.
Additional file 4: Cytotoxicity of receptor antagonists. Cytotoxicity of
CB1 receptor antagonist (AM251), TRPV1 receptor antagonist
(capsazepine), PPARa and PPARg receptor antagonists (GW6471 and
T0070907 respectively) and GPR55 receptor antagonist (cannabidiol, CBD).
B16 cells were incubated with the antagonists for 72 h. A MTT test was
used to evaluate the percentage of viable cells remaining after
treatment. Data are expressed as percentage of the vehicle control and
are the mean of three experiments performed in quintuplicate.
Additional file 5: Effect of MAFP, CAY10499 and URB597 incubation
on PEA and 2-AG levels in B16 cells.( A) MAFP, but not CAY10499,
increases intracellular levels of PEA. We found in control cells 25.4 ± 3.8
pmol of PEA/10
7 cells. (B) MAFP and CAY10499, but not URB597, increase
intracellular levels of 2-AG. We found in control cells 29.9 ± 4.8 pmol of
2-AG/10
7 cells. Levels were measured by HPLC-MS. B16 cells (10
7 cells)
were incubated for 8 h with URB597, CAY10499 or MAFP (1 μM). Data
are the mean of three experiments performed in quadruplicate and are
expressed as percentage of the vehicle control. Significantly different (*P
< 0.05; **P < 0.01; ***P < 0.001) from vehicle incubation.
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AEA: Anandamide N-arachidonoylethanolamine; 2-AG: 2-
arachidonoylglycerol; CB1: Cannabinoid receptor 1; CB2: Cannabinoid
receptor 2; FAAH: Fatty acid amide hydrolase; MAGL: Monoacylglycerol
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